Henry Schein appoints industry veteran Frederick M. Lowery as new CEO

Henry Schein has appointed Frederick M. Lowery as its new chief executive officer, effective March 2, the company announced Monday. Lowery will also join the company’s board of directors.

Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue as chairman of the board to support a smooth leadership transition.

“I am honored to join Henry Schein at such a pivotal moment,” Lowery said in a statement. “This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service and partnership. I look forward to working with Team Schein to build on the strong foundation established by Stan while accelerating value creation.”

Related: Henry Schein One partners with Amazon Web Services to power its AI-driven dental ecosystem

More than two decades of healthcare leadership

Lowery brings more than 20 years of healthcare industry experience to Henry Schein, with a track record of scaling complex businesses and driving sustained growth. Most recently, he served as executive vice president and president of Laboratory Products and BioProduction at Thermo Fisher Scientific, where he led the Fisher Scientific distribution channel’s above-market performance.

His experience overseeing distribution and owned product businesses — including manufacturing, research and development, marketing and sales — closely aligns with Henry Schein’s business model and supports the company’s continued execution of its BOLD+1 strategic plan.

Before joining Thermo Fisher, Lowery held leadership roles at Maytag Corporation and General Motors. He holds a master’s degree in manufacturing management from Kettering University and a bachelor’s degree in mechanical engineering from Tennessee Technological University.

Related: Investment company buys Florida distribution centre for $21.1M and leases it to Henry Schein

Bergman welcomed the appointment, citing Lowery’s operational background and leadership approach.

“Beyond his extensive experience, he brings a leadership philosophy that reflects the values that have long defined our company,” Bergman said. “Fred understands the critical role we play in supporting dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth.”

Phil Laskawy, lead director and chair of the company’s nominating and governance committee, said the board conducted a comprehensive search before selecting Lowery.

“With extensive commercial, logistics and manufacturing expertise, and a strong focus on customer satisfaction, he has the capabilities necessary to accelerate growth and value creation,” Laskawy said.

Max Lin, board member, vice chair of the nominating and governance committee, and partner at KKR, said Lowery’s appointment supports Henry Schein’s long-term strategy.

“We believe Fred brings a unique combination of healthcare distribution experience, operational best practices and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a world-class business,” Lin said.